Reference(s)
Click here to return to the Reference Table

Cancer type: Synovial Sarcoma


HGF/SF expression

Reference Number: 146
Kuhnen, C., Tolnay, E., Steinau, H. U., Voss, B. & Muller, K. M. Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma. Virchows Arch 432, 337-42 (1998).
PubMed link      E-mail link

Reference Number: 147
Motoi, T. et al. Coexpression of hepatocyte growth factor and c-Met proto-oncogene product in synovial sarcoma. Pathol Int 48, 769-75 (1998).
PubMed link      E-mail link

Reference Number: 148
Oda, Y. et al. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol 31, 185-92 (2000).
PubMed link      E-mail link

Met expression

Reference Number: 146
Kuhnen, C., Tolnay, E., Steinau, H. U., Voss, B. & Muller, K. M. Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma. Virchows Arch 432, 337-42 (1998).
PubMed link      E-mail link

Reference Number: 147
Motoi, T. et al. Coexpression of hepatocyte growth factor and c-Met proto-oncogene product in synovial sarcoma. Pathol Int 48, 769-75 (1998).
PubMed link      E-mail link

Reference Number: 148
Oda, Y. et al. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol 31, 185-92 (2000).
PubMed link      E-mail link

Reference Number: 1517
Yasui H1, Naka N2, Imura Y3, Outani H3, Kaneko K3, Hamada K3, Sasagawa S4, Araki N5, Ueda T6, Itoh K4, Myoui A3, Yoshikawa H3. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001. Cancer Lett. 347, 114-22 (2014)
PubMed link      E-mail link

Poor Prognosis

Mutation of Met

In vitro studies

Reference Number: 498
Watanabe T, Tsuda M, Makino Y, Ichihara S, Sawa H, Minami A, Mochizuki N, Nagashima K, Tanaka S. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines. Mol Cancer Res. 4, 499-510 (2006)
PubMed link      E-mail link

Animal models

Therapeutic Development

Reference Number: 1517
Yasui H1, Naka N2, Imura Y3, Outani H3, Kaneko K3, Hamada K3, Sasagawa S4, Araki N5, Ueda T6, Itoh K4, Myoui A3, Yoshikawa H3. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001. Cancer Lett. 347, 114-22 (2014)
PubMed link      E-mail link

Reviews